HK1119578A1 - Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease - Google Patents

Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Info

Publication number
HK1119578A1
HK1119578A1 HK08111743.9A HK08111743A HK1119578A1 HK 1119578 A1 HK1119578 A1 HK 1119578A1 HK 08111743 A HK08111743 A HK 08111743A HK 1119578 A1 HK1119578 A1 HK 1119578A1
Authority
HK
Hong Kong
Prior art keywords
inflammatory disease
antagonists
ocular inflammatory
treat autoimmune
autoimmune ocular
Prior art date
Application number
HK08111743.9A
Other languages
English (en)
Inventor
Daniel J Cua
Robert A Kastelein
Van T Tsai
Rachel Caspi
Phyllis Silver
Dror Luger
Original Assignee
Schering Corp
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686002&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1119578(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Us Gov Health & Human Serv filed Critical Schering Corp
Publication of HK1119578A1 publication Critical patent/HK1119578A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HK08111743.9A 2005-09-01 2008-10-24 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease HK1119578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71379205P 2005-09-01 2005-09-01
US83731206P 2006-08-11 2006-08-11
PCT/US2006/033840 WO2007027761A2 (en) 2005-09-01 2006-08-30 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Publications (1)

Publication Number Publication Date
HK1119578A1 true HK1119578A1 (en) 2009-03-13

Family

ID=37686002

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08111743.9A HK1119578A1 (en) 2005-09-01 2008-10-24 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Country Status (22)

Country Link
US (6) US20080199460A1 (da)
EP (3) EP2116258A1 (da)
JP (3) JP2009507023A (da)
CN (1) CN101296706B (da)
AT (1) ATE445415T1 (da)
AU (1) AU2006284841B2 (da)
BR (1) BRPI0615297A2 (da)
CA (1) CA2621086A1 (da)
CY (1) CY1110606T1 (da)
DE (1) DE602006009834D1 (da)
DK (1) DK1933869T3 (da)
ES (1) ES2333260T3 (da)
HK (1) HK1119578A1 (da)
HR (1) HRP20100014T1 (da)
NO (1) NO20081574L (da)
NZ (2) NZ566424A (da)
PL (1) PL1933869T3 (da)
PT (1) PT1933869E (da)
RS (1) RS51142B (da)
SI (1) SI1933869T1 (da)
TW (2) TWI463993B (da)
WO (1) WO2007027761A2 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP3006466B1 (en) * 2005-12-02 2018-08-01 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CN103933573A (zh) * 2007-02-28 2014-07-23 默沙东公司 用于治疗免疫病症的联合治疗
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009014263A1 (ja) * 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
US20110212100A1 (en) * 2007-08-15 2011-09-01 Tracy Keller Methods for modulating development and expansion of il-17 expressing cells
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2711696C (en) 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
US20110052600A1 (en) 2008-02-21 2011-03-03 Amgen Inc. Il-17ra-il-17rb antagonists and uses thereof
MX2010012090A (es) 2008-05-05 2011-04-11 Novimmune Sa Anticuerpos anti-il 17 a/il-17f de reactividad cruzada y metodos de uso de los mismos.
JP2012515164A (ja) * 2009-01-09 2012-07-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜障害を処置するための治療組成物
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
BRPI1011535A2 (pt) * 2009-04-01 2016-03-29 Genentech Inc tratamento de distúrbios resistentes à insulina.
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
US9301997B2 (en) 2009-09-21 2016-04-05 Peptinov Sas Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
SI3295957T1 (sl) 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
DK2598526T3 (da) 2010-07-29 2018-11-19 Eleven Biotherapeutics Inc Kimæriske il-1-receptortype-i-agonister og -antagonister
EP3299390A1 (en) * 2010-10-08 2018-03-28 Novartis AG Methods of treating psoriasis using il-17 antagonists
US8778346B2 (en) 2010-11-04 2014-07-15 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US20140314798A1 (en) * 2011-10-21 2014-10-23 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
PE20142422A1 (es) 2012-04-05 2015-01-21 Hoffmann La Roche Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
JP6293120B2 (ja) 2012-05-03 2018-03-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ＩＬ−２３ｐ１９抗体
EP3456741B1 (en) 2012-05-22 2020-12-16 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
EP2931311A4 (en) * 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
BR112015022587A2 (pt) 2013-03-13 2017-10-24 Eleven Biotherapeutics Inc formulações de citocina quimérica para entrega ocular
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
EP3189153B1 (en) 2014-09-03 2021-06-16 Boehringer Ingelheim International GmbH Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
ES2658310T3 (es) 2014-12-23 2018-03-09 4D Pharma Research Limited Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación
US10058705B2 (en) 2014-12-31 2018-08-28 Micron Devices Llc Antenna assembly
JP2018506275A (ja) * 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
EP3650033B1 (en) 2015-06-15 2022-02-16 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MD3307288T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
HUE045754T2 (hu) 2015-06-15 2020-01-28 4D Pharma Res Ltd Blautia stercosis és wexlerae gyulladásos és autoimmun betegségek kezelésében történõ alkalmazásra
RU2018113694A (ru) 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
TWI797067B (zh) 2015-11-20 2023-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CN114712405A (zh) 2016-03-04 2022-07-08 4D制药有限公司 包含细菌菌株的组合物
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018215758A1 (en) 2017-05-22 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strains
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
PT3638271T (pt) 2017-06-14 2021-01-05 4D Pharma Res Ltd Composições contendo estirpes bacterianas
CA3066561C (en) 2017-06-14 2022-07-19 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus megasphera and uses thereof
KR20230065254A (ko) * 2020-08-05 2023-05-11 신테카인, 인크. IL27Rα 결합 분자 및 사용 방법
WO2023056485A1 (en) * 2021-10-03 2023-04-06 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
ATE452207T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5869286A (en) 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
CA2412626C (en) 2000-06-22 2013-10-22 Amgen Inc. Il-17 molecules and uses thereof
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
JP5477998B2 (ja) * 2002-10-30 2014-04-23 ジェネンテック， インコーポレイテッド Ｉｌ−１７産生の阻害
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
CN1759123B (zh) 2003-03-10 2011-04-13 先灵公司 Il-23激动剂及拮抗剂的用途；相关试剂
CA2525184C (en) * 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
CA2565566A1 (en) * 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
WO2006007486A2 (en) * 2004-07-01 2006-01-19 New York University COMPOSITIONS AND METHODS FOR MODULATION OF RORϜt
DE102005032499B4 (de) * 2004-07-13 2009-10-22 Lg Electronics Inc. Dämpfer zur Vibrationsdämpfung und damit ausgerüstete Waschmaschine
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006060194A1 (en) * 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
EP1827462A4 (en) * 2004-11-24 2012-01-04 Therakine Ltd IMPLANT FOR INTRAOCULAR DRUG DELIVERY
WO2006068987A2 (en) * 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
JP2008523842A (ja) 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
AR052289A1 (es) * 2005-02-14 2007-03-07 Wyeth Corp Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f y sus usos
CN103172739A (zh) 2005-06-30 2013-06-26 Abbvie公司 Il-12/p40结合蛋白
JP2009501006A (ja) * 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds

Also Published As

Publication number Publication date
BRPI0615297A2 (pt) 2011-05-17
US20100111950A1 (en) 2010-05-06
WO2007027761A2 (en) 2007-03-08
EP2322219A2 (en) 2011-05-18
AU2006284841A1 (en) 2007-03-08
EP1933869A2 (en) 2008-06-25
JP2009507023A (ja) 2009-02-19
HRP20100014T1 (hr) 2010-02-28
EP1933869B1 (en) 2009-10-14
JP2014005285A (ja) 2014-01-16
NZ566424A (en) 2011-10-28
US20100111954A1 (en) 2010-05-06
NO20081574L (no) 2008-05-30
WO2007027761A3 (en) 2007-05-03
SI1933869T1 (sl) 2010-02-26
PT1933869E (pt) 2009-12-24
US8524230B2 (en) 2013-09-03
CN101296706B (zh) 2011-11-30
AU2006284841B2 (en) 2012-11-08
JP2011184466A (ja) 2011-09-22
CN101296706A (zh) 2008-10-29
TWI372061B (en) 2012-09-11
EP2322219A3 (en) 2013-06-05
US20080199460A1 (en) 2008-08-21
ES2333260T3 (es) 2010-02-18
JP5462838B2 (ja) 2014-04-02
TW200800259A (en) 2008-01-01
TW201235050A (en) 2012-09-01
US20140248279A1 (en) 2014-09-04
DK1933869T3 (da) 2010-03-01
EP2116258A1 (en) 2009-11-11
NZ595262A (en) 2013-03-28
DE602006009834D1 (de) 2009-11-26
US20130323251A1 (en) 2013-12-05
US20110142831A1 (en) 2011-06-16
TWI463993B (zh) 2014-12-11
PL1933869T3 (pl) 2010-06-30
CA2621086A1 (en) 2007-03-08
CY1110606T1 (el) 2015-04-29
RS51142B (sr) 2010-10-31
ATE445415T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
TWI372061B (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2010144721A3 (en) Model systems and treatment regimes for treatment of neurological disease
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2007098089A3 (en) Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
IN2012DN02471A (da)
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2010101301A9 (en) Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
EA200970293A1 (ru) Новые производные 5-тиоксилопиранозы
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности

Legal Events

Date Code Title Description
REV Revocation after opposition